Excerpt from an article titled “Global Trends in clinical studies of Ivermectin in COVID-19”, published in THE JAPANESE JOURNAL OF ANTIBIOTICS 74―1 Mar. 2021
Numerous clinical trials have been conducted in various countries
around the world. As of the 30th of January 2021, a total of 91 trials in 27 countries
has been recorded at these registration sites. There are 43 trials in phase 3 and 27
trials in phase 2, along with 17 observational studies. This includes 80 trials being
conducted for therapeutic purposes and 11 for the purpose of preventing the onset of
disease in close contacts and healthcare professionals.
Furthermore, by the 27th of February, the results of 42 clinical trials, including
approximately 15,000 patients (both registered and unregistered studies) have been
subjected to a meta-analysis after exclusion of biasing factors. It was found that 83%
showed improvements with early treatment, 51% improved during late-stage
treatment, and there was an 89% prevention of onset rate noted. This confirms the
usefulness of ivermectin. Since it is a meta-analysis based on 42 test results, it is
estimated that the probability of this comprehensive judgment being a mistake is as
low as 1 in 4 trillion. In addition, two separate meta-analyses also showed the
usefulness of ivermectin and their conclusions were presented to the WHO and the
US FDA with a request for an expansion of the indication of ivermectin in the
treatment of COVID-19.
